Suzetrigine, a Non-Opioid Small-Molecule Analgesic: Mechanism of Action, Clinical, and Translational Science
Abstract
ABSTRACT The discovery and approval of Suzetrigine (VX‐548, Journavx) marks a significant breakthrough in pain management. It is the first non‐opioid analgesic approved since celecoxib in 1998. Suzetrigine selectively blocks voltage‐gated sodium channel Na v 1.8 and acts exclusively on peripheral nociceptors without crossing the blood–brain barrier, providing analgesia while sparing central nervous system side effects such as dependence, addiction, sedation, and respiratory depression. In vitro experiments have demonstrated that Suzetrigine is a state‐dependent inhibitor with nanomolar potency against human Na v 1.8, exhibiting > 31,000‐fold selectivity compared to other subtypes of sodium channels and molecular targets. Suzetrigine is rapidly absorbed following oral administration with peak plasma concentrations ( T max ) in approximately 3 h under fasting conditions and an effective half‐life ( t 1/2 ) of 23.6 h. Suzetrigine is primarily eliminated via hepatic metabolism. Recent phase II and III clinical trials have validated Suzetrigine's efficacy in acute postoperative pain settings, demonstrating statistically significant reductions in pain intensity over 48 h following abdominoplasty and bunionectomy. Additionally, Suzetrigine has shown favorable safety and tolerability in broader acute pain indications and is under continued investigation for the treatment of chronic neuropathic conditions such as diabetic peripheral neuropathy. Pharmacokinetic and pharmacodynamic…
Read the paper
Related studies
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
- Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
- Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
- Celecoxib or naproxen treatment does not benefit depressive symptoms in persons aged 70 and over: findings from a randomized controlled trial
- Comparative Clinical Effectiveness of Nonsurgical Treatment Methods in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial
- Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.